Раздел 3.71. Fletcher, D. M. World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of Soft Tissue fed Bone / D. M. Fletcher, K. Unni, F. Mertens. Lyon: IARC Press, 2002.
2. Berri, R. N. Desmoid tumor: current multidisciplinary approaches /Ann. Plast. Surg. ‒ 2011. T. 67, N 5. P. 551–564. Fibromatoses / Int J Cancer. 2011 Jul;129(1):256-61. Epub 2010 Nov 3.
3. J. Clinical reports on the surgical practice of the Glasgow Royal Infirmany. Glasgow, D. Robertson, 1832, 63-66.
4. Muller J. Ueber den feinen Bau und die Formen der krankhaften Geschwulste. (About the fine structure and types of pathological tumors). Berlin: Reimer G. Erste Lieferung. 1838: 60.
5. Dormans J.P., Spiegel D, Meyer J., et al. Overview Plus. Fibromatosis in childhood: The desmoid/fibromatosis complex. Med Pediatr Oncol 2001; 37: 126-131.
6. Eich G.F., Hoeffel J.C., et al. Fibrous tumors in children: imaging features
of a heterogeneous group of disorders. Pediatr Radiol 1998; 28: 500-509.
7. Reitamo J.J., Hayry P., Nykyri E., Saxen E. The desmoid tumor. I. Incidence, sex-, age- and anatomical disrtribution in the Finnish population. Am J Clin Pathol 1982; 77: 665-73.
8. Svanvik J., Knutsson F., Jansson R., Ekman H. Desmoid tumor in the abdominal wall after treatment with high doze estradiol for prostatic cancer. Acta Chir Scand 1982; 148 (3): 301-303.
9. Nieuwenhuis M.H., Casparie M., Mathus-Vliegen L.M., Dekkers O..M, Hogendoorn P.C., Vasen H.F. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type.
10. Koskenvuo L., Peltomäki P., Renkonen-Sinisalo L., Gylling A., Nieminen T.T., Ristimäki A., Lepistö A. Desmoid tumor patients carry an elevated risk of familial adenomatous polyposis. /J Surg Oncol. 2016 Feb;113(2):209-12.
11. Schlemmer M. Desmoid tumors and deep fibromatoses /Hematol Oncol Clin North Am. 2005;19(3):565.
12. Cheon, S. S. Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts / Exp. Cell. Res. 2004 Feb 15. N 293 (2). P. 267–274.
13. Li C., Bapat B., Alman B.A. Adenomatous polyposis coli gene mutation alters proliferation through its beta-catenin-regulatory function in aggressive fibromatosis (desmoid tumor) /Am J Pathol. 1998;153(3):709.
14. Garvey, P. B. Complex reconstruction of desmoid tumor resections does not increase desmoid tumor recurrence / Patrick B. Garvey, Justin H. Booth, Donald P. Baumann [et al.] // J. Am. Coll. Surg. 2013. P. 472–480.
15. Kumar, V. Desmoid tumors: experience of 32 cases and review of the literature / Indian J Cancer.2009. Vol. 46, N 1. P. 34–39.
16. Хомяков, В. М. Опыт хирургического лечения десмоидных фибром абдоминальной и интраабдоминальной локализации / В. М. Хомяков, В. В. Черемисов, А. В. Чайка, Л. А. Вашакмадзе, С. Л. Дарьялова, О. В. Новикова, А. К. Кострыгин // Хирургия. 2014. № 11. C. 17–25.
17. National Comprehensive Cancer Network Guidelines in Oncology // Soft Tissue Sarcoma ‒ URL:
www.nccn.org.
18. Lazar, A. J. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors / A. J. Lazar, D. Tuvin, S. Hajibashi, et al. // Am. J. Pathol. 2008. V. 173, № 5. P. 1518–1527.
19. Singer, S. Molecular biology of soft tissue sarcoma / S. Singer // Cancer Principles and Practice of Oncology / S. Singer, T. Nielsen, C. R. Antonescu. 9th ed. 2011.
20. Tejpar, S. Predominance of beta-catenin mutations and beta-catenin dysregulation
in sporadic aggressive fibromatosis (desmoid tumor) / S. Tejpar, F. Nollet, C. Li, et al. // Oncogene. 1999. V. 18, № 47. P. 6615–6620.
21. Otero S., Moskovic E.C., Strauss D.C., Benson C., Miah A.B., Thway K., Messiou C. Desmoid-type fibromatosis. Clin Radiol. 2015 Sep;70(9):1038-45. doi: 10.1016/j.crad.2015.04.015. Epub 2015 Jul 7. PMID: 26162574.
22. Gounder M.M., Maddux L., Paty J., Atkinson T.M. Prospective development
of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis. /Cancer. 2020;126(3):531. Epub 2019 Nov 6.
23. Zreik, R. T. Morphologic Spectrum of Desmoid-Type Fibromatosis / R. T. Zreik, K. J. Fritchie // Am. J. Clin. Pathol. 2016 Mar. N 145 (3). P. 332–340.
24. Dubova, E. A. Bull Immunohistochemical characteristics of desmoid tumors E. A. Dubova, T. V. Sidorenko, A. I. Shchyogolev [et al.] // Exp. Biol. Med. 2012 Apr. N 152 (6). P. 743–747.
25. Широков, В. С. Лучевая диагностика десмоидных опухолей / В. С. Широков, Г. Г. Кармазановский, Ю. А. Степанова [и др.] // Медицинская визуализация. 2011.№ 3. С. 134–135.
26. Braschi-Amirfarzan, M. Role of Imaging in Management of Desmoid-type Fibromatosis: A Primer for Radiologists / M. Braschi-Amirfarzan, A. R. Keraliya, K. M. Krajewski [et al.] // Radiographics. 2016 May–Jun. N 36(3). P. 767–82. DOI: 10.1148/rg.2016150153.
27. Milos, R. I. Superficial desmoid tumors: MRI and ultrasound imaging characteristics / R. I. Milos, T. Moritz, M. Bernathova [et al.] // Eur. J. Radiol. 2015 Nov. N 84 (11).P. 2194–2201.
28. Liu, D. Musculoskeletal desmoid tumours: Diagnostic imaging appearances / D. Liu, W. Perera, S. Schlicht [et al.] // J. Med. Imaging Radiat. Oncol. 2015 Aug. N 59(4). P. 461–467.
29. Kanthan, G. L. Desmoid Tumor Showing Intense Uptake on 68Ga PSMA-HBED-CC PET/CT / G. L. Kanthan, E. Hsiao, A. Kneebone [et al.] // Clin. Nucl. Med. 2016 Jun. N 41 (6). P. 508–509.
30. Kasper, B. Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib / B. Kasper, A. Dimitrakopoulou-Strauss, L. G. Strauss [et al.] // Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37, N 10. P. 1876–1882.
31. Timbergen M.J.M., Starmans M.P.A., Padmos G.A.., Grünhagen D.J, van Leenders G.J.L.H., Hanff D.F., Verhoef C., Niessen W.J., Sleijfer S., Klein S., Visser J.J. Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics. Eur J Radiol. 2020 Oct; 131:109266. doi: 10.1016/j.ejrad.2020.109266. Epub 2020 Sep 8. PMID: 32971431.
32. Lacka D.E., Nasierowska-Guttmejer A. Fibromatosis-immunohistochemical evaluation, differential diagnosis from gastrointestinal tumors, and other mesenchymal tumours. Prz Gastroenterol. 2019;14(1):79-85. doi: 10.5114/pg.2019.83429. Epub 2019 Mar 12. PMID: 30944681; PMCID: PMC6444105.
33. Cărăuleanu A., Popovici R.M., Costea C.F., Mogoş R.A., Scripcariu D.V., Florea I.D., Cheaito A., Tănase A.E., Haba R.M., Grigore M. Abdominal wall endometriosis versus desmoid tumor - a challenging differential diagnosis. Rom J Morphol Embryol. 2020;61(1):45-50. doi: 10.47162/RJME.61.1.05. PMID: 32747894; PMCID: PMC7728103.
34. Manchanda A.S., Narang R.S., Arora P.C., Singh B., Walia S. Aggressive desmoplastic fibromatosis - a clinicians dilemma case report and review of literature. J Clin Diagn Res. 2013 Nov;7(11):2639-41. doi: 10.7860/JCDR/2013/6277.3636. Epub 2013 Nov 10. PMID: 24392428; PMCID: PMC3879825.
35. Kasper, B. An update on the management of sporadic desmoid-type fibromatosis:
a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / B. Kasper [et al.]; Soft Tissue and Bone Sarcoma Group (STBSG) // Annals of Oncology. 2017. N 28. P. 2399–2408.
36. Mueller, C. Primary and recurrent sporadic desmoids: Prognostic factors influencing recurrence-free survival after complete gross resection / C. Mueller [et al.] // Int. J. Surg. 2016. V. 31. P. 63–70.
37. Nuyttens, J. J. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles / J. J. Nuyttens, P. F. Rust, C. R. Thomas [et al.] // Cancer. 2000.Vol. 88, N 7. P. 1517–1523.
38. Harati, K. Effect of surgical margins on prognosis in aggressive fibromatosis: A single-institutional analysis of 90 patients / K. Harati, A. Jaenisch, B. Behr [et al.] // Oncol. Lett. 2017 Nov. N 14 (5). P. 5129–5134.
39. Janssen, M. L. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis / M. L. Janssen [et al.] // Br. J. Surg. 2017. V. 104, N 4. P. 347–357.
40. Shido, Y. Surgical treatment for local control of extremity and trunk desmoid tumors / Y. Shido [et al.] // Arch. Orthop. Trauma Surg. 2009. V. 129, N 7. P. 929–933.
41. National Comprehensive Cancer Network Guidelines in Oncology // Soft Tissue Sarcoma. ‒ URL:
www.nccn.org.
42. Desmoid Tumor Working Group The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients Eur J Cancer2020 Mar; 127:96-107.
43. Garcia-Ortega D.Y., Martín-Tellez K.S., Cuellar-Hubbe M., Martínez-Said H. et al. Desmoid-Type Fibromatosis. Cancers 2020; 12, 1851.
44. Zenzri Y., Yahyaoui Y., Charfi L., Ghodhbani Z., Letaief F., Ayadi M., Mezlini A. The Management of Desmoid Tumors: A Retrospective Study of 30 Cases. Int J Surg Oncol. 2020 Jul 18; 2020:9197216. doi: 10.1155/2020/9197216.
45. Kasper, Bernd. New treatments for desmoid tumors. Current Opinion in Oncology 35(4): p 292-295, July 2023. | DOI: 10.1097/CCO.0000000000000953.
46. Mrinal Gounder, M.D., Ravin Ratan, M.D., Thierry Alcindor, M.D. et al. Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors New England Journal of Medicine 2023; DOI: 10.1056/NEJMoa2210140 PMID 388:898-912.
47. Martínez Trufero J., Pajares Bernad I., Torres Ramón I., Hernando Cubero J., Pazo Cid R. Desmoid-Type Fibromatosis: Who, When, and How to Treat. Curr Treat Options Oncol. 2017 May;18(5):29. doi: 10.1007/s11864-017-0474-0. PMID: 28439797.
48. Huang, K. Prognostic factors influencing event-free survival and treatments
in desmoid-type fibromatosis: analysis from a large institution / K. Huang [et al.] // Am. J. Surg. 2014. V. 207, N 6. P. 847–854.
49. Koskenvuo L., Ristimäki A., Lepistö A. Comparison of sporadic and FAP-associated desmoid-type fibromatoses. J Surg Oncol. 2017 Nov;116(6):716-721. doi: 10.1002/jso.24699. Epub 2017 Jun 1. PMID: 28570749.